Abstract
Drug discovery and development are often hampered by lack of target identification and clinical tractability. Repurposing of approved drugs to life-threatening diseases such as leukemia is emerging as a promising alternative approach. Connectivity mapping systems link approved drugs with disease-related gene signatures. Relevant preclinical models provide essential tools for system validation and proof-of-concept studies. Herein we describe procedures aimed at generating disease-based gene signatures and applying them to established cross-referencing databases of potential candidate drugs. As a proof of principle, we present the identification of Entinostat as a candidate drug for the treatment of HOX-TALE-related leukemia.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / pharmacology*
-
Benzamides / administration & dosage
-
Benzamides / pharmacology
-
Cell Line, Tumor
-
Databases, Genetic
-
Disease Models, Animal
-
Drug Discovery*
-
Drug Evaluation, Preclinical
-
Gene Expression Profiling
-
Gene Expression Regulation, Leukemic / drug effects*
-
Histone Deacetylase Inhibitors / administration & dosage
-
Histone Deacetylase Inhibitors / pharmacology
-
Homeodomain Proteins / genetics*
-
Homeodomain Proteins / metabolism
-
Humans
-
Leukemia / drug therapy
-
Leukemia / genetics*
-
Leukemia / metabolism
-
Leukemia / pathology
-
Mice
-
Pyridines / administration & dosage
-
Pyridines / pharmacology
-
Xenograft Model Antitumor Assays
Substances
-
Antineoplastic Agents
-
Benzamides
-
Histone Deacetylase Inhibitors
-
Homeodomain Proteins
-
Pyridines
-
entinostat